Austin Top 50
Author:
Celularity Inc.
Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
April 17, 2026
Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities
March 12, 2026
Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy
March 10, 2026